nach oben

Erschienen in:

06.08.2020 | Letter to the Editor

Successful treatment of EBV-related lymphoproliferative disease after heart transplantation with autologous hematopoietic stem cell transplantation despite transient heart failure associated with engraftment syndrome

verfasst von: Megumi Yasunaga, Yohei Yasuda, Akira Honda, Hiroaki Maki, Kazuhiro Toyama, Yosuke Masamoto, Chie Bujo, Eisuke Amiya, Masaru Hatano, Minoru Ono, Issei Komuro, Mineo Kurokawa

Erschienen in: Annals of Hematology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Martínez-Calle N, Alfonso A, Rifón J, Herrero I, Errasti P, Rábago G, Merino J, Panizo Á, Pardo J, Prósper F, García-Muñoz R, Lecumberri R, Panizo C (2017) First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study. Eur J Haematol 98(1):38–43CrossRef

Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, Beneyto I, Espí J, Gómez-Codina J, Iacoboni G, Jarque I, López-Andújar R, Mayordomo-Aranda E, Montalar J, Pastor A, Pastor M, Piñana JL, Rojas-Ferrer N, Sánchez-Lázaro I, Sandoval J, Sanz G, Sanz MÁ, Solé A, Sanz J (2019) Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma 60(1):142–150CrossRef

Kumarasinghe G, Lavee O, Parker A, Nivison-Smith I, Milliken S, Dodds A, Joseph J, Fay K, Ma DD, Malouf M, Plit M, Havryk A, Keogh AM, Hayward CS, Kotlyar E, Jabbour A, Glanville AR, Macdonald PS, Moore JJ (2015) Post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors. J Heart Lung Transplant 34(11):1406–1414CrossRef

Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S (2017) Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol 35(5):536–543CrossRef

Jain MD, Lam R, Liu Z, Stubbins RJ, Kahlon A, Kansara R, Goswami R, Humar A, Prica A, Sehn LH, Slack GW, Crump M, Savage KJ, Peters AC, Kuruvilla J (2020) Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder. Br J Haematol 189(1):97–105CrossRef

DeStefano CB, Malkovska V, Rafei H, Shenoy A, Fitzpatrick K, Aggarwal A, Catlett JP (2017) DA-EPOCH-R for post-transplant lymphoproliferative disorders. Eur J Haematol 99(3):283–285CrossRef

Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Fujiwara S-I, Okazuka K, Hatano K, Sato K, Iekuni O, Ohmine K, Suzuki T, Muroi K, Kako S, Kanda Y (2016) Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol 95(9):1513–1519CrossRef

Titel: Successful treatment of EBV-related lymphoproliferative disease after heart transplantation with autologous hematopoietic stem cell transplantation despite transient heart failure associated with engraftment syndrome
verfasst von: Megumi Yasunaga
Yohei Yasuda
Akira Honda
Hiroaki Maki
Kazuhiro Toyama
Yosuke Masamoto
Chie Bujo
Eisuke Amiya
Masaru Hatano
Minoru Ono
Issei Komuro
Mineo Kurokawa
Publikationsdatum: 06.08.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 4/2021
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04198-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Successful treatment of EBV-related lymphoproliferative disease after heart transplantation with autologous hematopoietic stem cell transplantation despite transient heart failure associated with engraftment syndrome

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma

Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort

Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial

Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin